Patents by Inventor Wolfgang Albrecht

Wolfgang Albrecht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240116931
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Application
    Filed: November 8, 2023
    Publication date: April 11, 2024
    Applicant: HEPAREGENIX GMBH
    Inventors: Brent PRAEFKE, Philip KLÖVEKORN, Roland SELIG, Wolfgang ALBRECHT, Stefan LAUFER
  • Patent number: 11912701
    Abstract: The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7. (I), wherein Rx, Ry, Rz and Rzz are selected from: a) Rx and Ry are F and Rz and Rzz are H; b) Rx, Ry and Rzz are independently halogen and Rz is H; c) Rx Rz and Rzz are independently halogen and Ry is H; and d) Rx Ry and Rz are independently halogen and Rzz is H.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: February 27, 2024
    Assignee: HepaRegeniX GmbH
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke
  • Publication number: 20240029965
    Abstract: An on-load tap-changer provides uninterrupted diverter switch operation between different winding taps of a tap-changing transformer. The on-load tap-changer includes: a flange module; and a union nut. The on-load tap-changer is configured to be fastened to the tap-changing transformer by the union nut and the flange module.
    Type: Application
    Filed: July 21, 2021
    Publication date: January 25, 2024
    Inventors: Christian HAMMER, Wolfgang ALBRECHT, Michael SCHMEISSER, Christian KOTZ
  • Patent number: 11858927
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 2, 2024
    Assignee: HepaRegeniX GmbH
    Inventors: Bent Praefke, Philip Klövekorn, Roland Selig, Wolfgang Albrecht, Stefan Laufer
  • Patent number: 11731968
    Abstract: Tricyclic mitogen-activated protein kinases kinase 4 (MKK4) inhibitor compounds useful for promoting liver regeneration or reducing hepatocyte death by selectively inhibiting MKK4 over protein kinases JNK and MKK7.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: August 22, 2023
    Assignee: HepaRegeniX GmbH
    Inventors: Michael Juchum, Roland Selig, Stefan Laufer, Wolfgang Albrecht
  • Publication number: 20230088395
    Abstract: The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK1 and MKK7. In formula (I), especially, Rw is —NR10SO2R12; either a) Rx and Ry are F and Rz and Rzz are H; or b) Rx, Ry and Rzz are independently halogen and Rz is H; R5 is substituted phenyl or pyrimidinyl.
    Type: Application
    Filed: January 13, 2021
    Publication date: March 23, 2023
    Inventors: Roland SELIG, Stefan LAUFER, Wolfgang ALBRECHT
  • Publication number: 20230017312
    Abstract: Compounds that are inhibitors of p38alpha and centrally available are described.
    Type: Application
    Filed: August 26, 2020
    Publication date: January 19, 2023
    Applicant: Synovo GmbH
    Inventors: Stefan Laufer, Wolfgang Albrecht, Pierre Koch, Niklas Walter
  • Publication number: 20220340561
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Application
    Filed: July 27, 2020
    Publication date: October 27, 2022
    Inventors: Bent PFAFFENROT, Roland SELIG, Stefan LAUFER, Wolfgang ALBRECHT
  • Publication number: 20220281864
    Abstract: The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
    Type: Application
    Filed: July 16, 2019
    Publication date: September 8, 2022
    Inventors: Wolfgang ALBRECHT, Stefan LAUFER, Roland SELIG, Phillip KLÖVEKORN, Bent PRÄFKE
  • Publication number: 20210261545
    Abstract: The invention relates to tricyclic compounds which are MKK4 (mitogen-activated protein kinase kinase 4) inhibitors which selectively inhibit protein kinase kinase MKK4 over protein kinases JNK and MKK7. They are useful for promoting liver regeneration or reducing or preventing hepatocyte death.
    Type: Application
    Filed: June 18, 2019
    Publication date: August 26, 2021
    Inventors: Michael JUCHUM, Roland SELIG, Stefan LAUFER, Wolfgang ALBRECHT
  • Patent number: 11040027
    Abstract: The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: June 22, 2021
    Assignee: Heparegenix GMBH
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke
  • Patent number: 11014206
    Abstract: A device (1) for exchanging at least one cutting component (2a) of a rotating tool (2), in particular a milling tool (2), and more particularly, a hollow milling tool for machining workpieces made of plastic. The device has an aligning device (5) for orientating a position of the cutting component (2a) relative to a rotational axis (2c) of the tool (2) and an exchanging device (6) for releasing the cutting component (2a) from a part (2b) that remains on the tool (2) and for attaching another cutting component (2a) to the part (2b) that remains on the tool (2).
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: May 25, 2021
    Assignee: MOROFF & BAIERL GMBH
    Inventors: Wolfgang Albrecht Moroff, Martin Mueller
  • Publication number: 20210078995
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Application
    Filed: January 30, 2019
    Publication date: March 18, 2021
    Inventors: Bent PRAEFKE, Philip KLÖVEKORN, Roland SELIG, Wolfgang ALBRECHT, Stefan LAUFER
  • Patent number: 10745357
    Abstract: The present invention relates (i) to a process for the preparation of quinolin-2-yl-phenylamine derivatives of formula (I) without a metal catalyst, and (ii) to soluble mineral acid or sulfonic acid salts of (8-chloro-quinolin-2-yl)-(4-trifluoromethoxyphenyl)-amine.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: August 18, 2020
    Inventors: Sebastian Rabe, Wolfgang Albrecht
  • Publication number: 20200239473
    Abstract: The present invention relates to novel compounds, e.g. for use as a medicament. In particular, the present invention relates to novel derivatives, preferably prodrugs, of licofelone suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases or inflammatory diseases. Further, the invention relates to a pharmaceutical composition comprising the novel compounds.
    Type: Application
    Filed: October 20, 2016
    Publication date: July 30, 2020
    Inventor: Wolfgang ALBRECHT
  • Patent number: 10669275
    Abstract: The present invention relates to co-crystals of ibrutinib and a pharmaceutical composition comprising the same as well as a method of preparing the same.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: June 2, 2020
    Assignee: ratiopharm GmbH
    Inventors: Wolfgang Albrecht, Jens Geier, Sebastian Rabe, David Perez Palacios
  • Publication number: 20200062713
    Abstract: The present invention relates (i) to a process for the preparation of quinolin-2-yl-phenylamine derivatives of formula (I) without a metal catalyst, and (ii) to soluble mineral acid or sulfonic acid salts of (8-chloro-quinolin-2-yl)-(4-trifluoromethoxyphenyl)-amine.
    Type: Application
    Filed: November 1, 2019
    Publication date: February 27, 2020
    Inventors: Sebastian RABE, Wolfgang ALBRECHT
  • Patent number: 10526326
    Abstract: The present invention relates to an adduct of palbociclib, a method of preparing the preparing the same, and a pharmaceutical composition comprising the same. More particularly, the invention provides a crystalline form of palbociclib, a method of preparing the same, as well as a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: January 7, 2020
    Assignee: ratiopharm GmbH
    Inventors: Jens Geier, Wolfgang Albrecht, Ludovic Coutable, Manfred Erdmann
  • Publication number: 20190365723
    Abstract: The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
    Type: Application
    Filed: January 17, 2018
    Publication date: December 5, 2019
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke
  • Patent number: 10464903
    Abstract: The present invention relates (i) to a process for the preparation of quinolin-2-yl-phenylamine derivatives of formula (I) without a metal catalyst, and (ii) to soluble mineral acid or sulfonic acid salts of (8-chloro-quinolin-2-yl)-(4-trifluoromethoxyphenyl)-amine.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 5, 2019
    Assignee: RATIOPHARM GMBH
    Inventors: Sebastian Rabe, Wolfgang Albrecht